Enasidenib + Rituximab
Phase 2RecruitingInterest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T-cell Lymphoma
Conditions
T-cell Lymphoma
Trial Timeline
Dec 24, 2024 → Dec 1, 2027
NCT ID
NCT06756308About Enasidenib + Rituximab
Enasidenib + Rituximab is a phase 2 stage product being developed by Bristol Myers Squibb for T-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06756308. Target conditions include T-cell Lymphoma.
What happened to similar drugs?
5 of 10 similar drugs in T-cell Lymphoma were approved
Approved (5) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06756308 | Phase 2 | Recruiting |
Competing Products
20 competing products in T-cell Lymphoma